- Home
- THC vs NBIX Comparison
THC vs NBIX Comparison
Compare THC & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THC | NBIX |
|---|---|---|
| Founded | 1967 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 14.4B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | THC | NBIX |
|---|---|---|
| Price | $198.91 | $152.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 20 |
| Target Price | ★ $222.00 | $175.10 |
| AVG Volume (30 Days) | ★ 1.0M | 923.0K |
| Earning Date | 10-28-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.44 |
| EPS | ★ 14.57 | 4.19 |
| Revenue | ★ $20,846,000,000.00 | $2,682,700,000.00 |
| Revenue This Year | $3.98 | $23.76 |
| Revenue Next Year | $4.39 | $18.01 |
| P/E Ratio | ★ $13.58 | $36.44 |
| Revenue Growth | N/A | ★ 19.61 |
| 52 Week Low | $109.82 | $84.23 |
| 52 Week High | $222.82 | $160.18 |
Technical Indicators
Market Signals| Indicator | THC | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 43.83 | 57.42 |
| Support Level | $194.54 | $151.59 |
| Resistance Level | $222.82 | $156.70 |
| Average True Range (ATR) | 6.57 | 4.18 |
| MACD | -1.62 | 0.35 |
| Stochastic Oscillator | 15.46 | 64.51 |
Price Performance
Historical ComparisonAbout THC Tenet Healthcare Corporation
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.